Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 07/22 10:00:00 pm
107.52 USD   +0.07%
07/15 CELGENE : EC approves Revlimid for mantle cell lymphoma
07/15 CELGENE : REVLIMID® (Lenalidomide) Approved by the European Commissi..
07/14 CELGENE : Danaher Announces Appointment of Robert J. Hugin to Danahe..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
07/21 DANAHER : Announces Appointment of Robert J. Hugin to Danaher Board
07/15 CELGENE : EC approves Revlimid for mantle cell lymphoma
07/15 CELGENE : REVLIMID® (Lenalidomide) Approved by the European Commission for the T..
07/14 CELGENE : Danaher Announces Appointment of Robert J. Hugin to Danaher Board
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/07DJJuno Shares Plunge as Drug Trial Placed on Hold After Patient Deaths
07/07 NASDAQ 100 MOVERS : Celg, bmrn
07/06DJBiotech Medivation Opens Door to Takeover Talks -- WSJ
07/06DJU.S. Stocks Rise, Led by Riskier Sectors
07/05DJSanofi, Medivation Start Takeover Talks -- 2nd Update
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
07/08 Medtech's 2016 stock surge confronts second-quarter test
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/22 Biogen Needs To Fill Pipeline Or Rethink Strategy
07/22 Healthcare ratings roundup - new coverage
07/22 BIOGEN BEATS, RAISES : Bye, Bye Bear Move, Hello Bull?
07/20 Biotechnology - ETF Overview
07/20 Celgene Pays Through The Nose For A Hand In Immune Checkpoints
Advertisement
Financials ($)
Sales 2016 11 013 M
EBIT 2016 5 759 M
Net income 2016 3 775 M
Debt 2016 6 600 M
Yield 2016 -
P/E ratio 2016 23,25
P/E ratio 2017 17,72
EV / Sales 2016 8,16x
EV / Sales 2017 6,62x
Capitalization 83 285 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 137 $
Spread / Average Target 27%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Jerome B. Zeldis Chief Medical Officer & CEO-Global Health
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-10.22%83 285
AMGEN, INC.2.06%124 454
GILEAD SCIENCES, INC.-14.47%115 269
REGENERON PHARMACEUTIC..-27.91%41 121
VERTEX PHARMACEUTICALS..-25.38%23 224
ACTELION LTD22.85%19 820
More Results